Fusion Pharmaceuticals

We are pleased to announce the proposed acquisition of Fusion Pharmaceuticals by AstraZeneca, which combines Fusion’s expertise and capabilities in #radioconjugates with AstraZeneca’s leadership in small molecules and biologics engineering to develop novel radioconjugates. This provides an opportunity to accelerate the development of our pipeline and establish next-generation radioconjugates as foundational regimens in #cancertherapy. Read the full press release here: https://lnkd.in/eBgQk4ur

We are pleased to announce the proposed acquisition of Fusion Pharmaceuticals by AstraZeneca, which combines Fusion’s expertise and capabilities in #radioconjugates with AstraZeneca’s leadership in small molecules and biologics engineering to develop novel radioconjugates. This provides an opportunity to accelerate the development of our pipeline and establish next-generation radioconjugates as foundational regimens in #cancertherapy. Read the full press release here: https://lnkd.in/eBgQk4ur

We are pleased to announce the proposed acquisition of Fusion Pharmaceuticals by AstraZeneca, which combines Fusion’s expertise and capabilities in #radioconjugates with AstraZeneca’s leadership in small molecules and biologics engineering to develop novel radioconjugates. This provides an opportunity to accelerate the development of our pipeline and establish next-generation radioconjugates as foundational regimens in #cancertherapy. Read the full press release here: https://lnkd.in/eBgQk4ur

The outlook for the potential of #radiopharmaceuticals to transform treatment for patients with #cancer is strong! We were pleased to see the field’s remarkable progress, as well as Fusion’s contributions to the advancement of targeted alpha therapies and next-generation #ADCs, spotlighted in today’s “Heard on the Street” column by David Wainer in the Wall Street Journal. The Fusion team looks forward to an exciting 2024 as we advance multiple #radiotherapy programs and execute with robust supply chain and manufacturing capabilities. Read the article here (subscription required): https://lnkd.in/eHiFsDFJ

We are pleased to announce an exclusive worldwide license agreement with Heidelberg University for our actinium-based PSMA targeted radiotherapy program: https://lnkd.in/e93e8zWn

Today John Valliant will give a virtual presentation at the Oppenheimer Healthcare Life Science Conference. Access the presentation here: https://lnkd.in/dwZCK6s

Today we were excited to kick off 2024 with clinical program and manufacturing operations updates, including progress with our FPI-2265 development program, an update on FPI-1434 Phase 1 Cohort 2 data and production of the first clinical doses from our manufacturing facility: https://lnkd.in/e8fMGZE8 #radiopharmaceuticals #radiopharmaceuticalmanufacturing #targetedalphatherapy

Today we were excited to announce the expansion of our collaboration with BWXT Medical Ltd. for actinium supply, supporting Fusion's ability to produce high purity actinium-225 at our GMP manufacturing facility.  #targetedalphatherapy #actinium #radiopharmaceuticals https://lnkd.in/ev_-DNH3

Today CEO John Valliant will present in a fireside chat at the Jefferies London Healthcare Conference. You can listen to the webcast, or a replay of the event, here on Fusion's website: https://lnkd.in/etfD-ynb

Glad to partner with Dr. Nordquist and his team for the benefit of patients.